Development of cell-cycle checkpoint therapy for solid tumors

Japanese Journal of Clinical Oncology

Volumn 45, Issue 12, 2015, Pages 1097-1102

  Tamura, Kenji ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Aurora kinase; CDK4 6 inhibitor; Cell cycle check point; Cyclin dependent kinase; Palbociclib; Polo like kinase

Indexed keywords

2 ALLYL 1 [6 (1 HYDROXY 1 METHYLETHYL) 2 PYRIDINYL] 6 [4 (4 METHYL 1 PIPERAZINYL)ANILINO] 1H PYRAZOLO[3,4 D]PYRIMIDIN 3(2H) ONE; 3 METHYL N [1,4,5,6 TETRAHYDRO 6,6 DIMETHYL 5 [(1 METHYL 4 PIPERIDINYL)CARBONYL]PYRROLO[3,4 C]PYRAZOL 3 YL]BUTANAMIDE; 5 (3 FLUOROPHENYL) N (3 PIPERIDINYL) 3 UREIDO 2 THIOPHENECARBOXAMIDE; ABEMACICLIB; ALISERTIB; AROMATASE INHIBITOR; AT 7519; AURORA KINASE; AZD 5438; CARBOPLATIN; CISPLATIN; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; DANUSERTIB; DINACICLIB; ERLOTINIB; FLAVOPIRIDOL; FULVESTRANT; GEMCITABINE; LETROZOLE; PACLITAXEL; PALBOCICLIB; PLACEBO; POLO LIKE KINASE; RIBOCICLIB; ROSCOVITINE; TAMOXIFEN; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VOLASERTIB; ANTINEOPLASTIC AGENT; AURKA PROTEIN, HUMAN; AURORA A KINASE; CELL CYCLE PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; ESTRADIOL; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ANTAGONIST; NITRILE; NUCLEAR PROTEIN; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE; TRIAZOLE DERIVATIVE; TUMOR MARKER; WEE1 PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER GROWTH; CELL CYCLE CHECKPOINT; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; DIARRHEA; FATIGUE; GLIOBLASTOMA; GLIOMA; HUMAN; IN VITRO STUDY; KIDNEY CANCER; LIPOSARCOMA; LIVER CELL CARCINOMA; LYMPHOMA; MANTLE CELL LYMPHOMA; MELANOMA; METASTASIS; MONOTHERAPY; NAUSEA; NEUROBLASTOMA; NEUTROPENIA; NON SMALL CELL LUNG CANCER; OVARY CANCER; OVARY CARCINOMA; PANCREAS CANCER; PERITONEUM TUMOR; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; REVIEW; SMALL CELL LUNG CANCER; SOLID TUMOR; UTERINE CERVIX CANCER; UTERINE TUBE TUMOR; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CANCER STAGING; CHEMISTRY; CLINICAL TRIAL (TOPIC); DISEASE FREE SURVIVAL; DRUG EFFECTS; FEMALE; MOLECULARLY TARGETED THERAPY; MORTALITY; PATHOLOGY; PROCEDURES; TRENDS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE INHIBITORS; AURORA KINASE A; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CELL CYCLE CHECKPOINTS; CELL CYCLE PROTEINS; CELL PROLIFERATION; CLINICAL TRIALS AS TOPIC; CYCLIN-DEPENDENT KINASES; DISEASE-FREE SURVIVAL; ESTRADIOL; ESTROGEN RECEPTOR ANTAGONISTS; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; NITRILES; NUCLEAR PROTEINS; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; TRIAZOLES;

EID: 84958957172     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyv131     Document Type: Review

References (35)

1. Suryadinata R, Sadowski M, Sarcevic B. Control of cell cycle progression by phosphorylation of cyclin-dependent kinase (CDK) substrates. Biosci Rep 2010;30:243-55.
2. Shackney SE, Shankey TV. Cell cycle models for molecular biology and molecular oncology: exploring new dimensions. Cytometry 1999;35:97-116.
3. Dickson MA. Molecular pathways: CDK4 inhibitors for cancer therapy. Clin Cancer Res 2014;20:3379-83.
4. Sutherland RL, Musgrove EA. CDK inhibitors as potential breast cancer therapeutics: new evidence for enhanced efficacy in ER+ disease. Breast Cancer Res 2009;11:112. doi:10.1186/bcr2454.
5. Dean JL, Thangavel C, McClendon AK, Reed CA, Knudsen ES. Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure. Oncogene 2010;29:4018-32.
6. Cadoo KA, Gucalp A, Traina TA. Palbociclib: an evidence-based review of its potential in the treatment of breast cancer. Breast Cancer (Dove Med Press) 2014;6:123-33.
7. Flaherty KT, Lorusso PM, Demichele A, et al. Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clin Cancer Res 2012;18:568-76.
8. DeMichele A, Clark AS, Tan KS, et al. CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: Phase II activity, safety, and predictive biomarker assessment. Clin Cancer Res 2015;21:995-1001.
9. Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol 2015;16:25-35.
10. Turner NC, Ro J, André F, Loi S, Verma S, et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med 2015; 373:209-19.
11. Dickson MA, Tap WD, Keohan ML, et al. Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified welldifferentiated or dedifferentiated liposarcoma. J Clin Oncol 2013;31: 2024-8.
12. Cen L, Carlson BL, Schroeder MA, et al. p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells. Neuro Oncol 2012;14:870-81.
13. Logan JE, Mostofizadeh N, Desai AJ, et al. PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity. Anticancer Res 2013;33:2997-3004.
14. Tate SC, Cai S, Ajamie RT, et al. Semi-mechanistic pharmacokinetic/ pharmacodynamic modeling of the antitumor activity of LY2835219, a new cyclin-dependent kinase 4/6 inhibitor, in mice bearing human tumor xenografts. Clin Cancer Res 2014;20:3763-74.
15. Sanchez-Martinez C, Gelbert L, Shannon H, et al. LY2835219, a potent oral inhibitor of the cyclin-dependent kinase 4 and 6 (CDK4/6) that crosses the blood-brain barrier and demonstrates in vivo activity against intracranial human brain tumor xenografts. Mol Cancer Ther 2011;10:B234.
16. Patnaik A, Rosen L, Tolaney S, et al. LY2835219, a novel cell cycle inhibitor selective for CDK4/6, in combination with fulvestrant for patients with hormone receptor positive(HR+) metastatic breast cancer. J Clin Oncol 2014;5s:A2528.
17. Infante JR, Shapiro G,Witteveen P, et al. A phase I study of the single-agent CDK4/6 inhibitor LEE011 in pts with advanced solid tumors and lymphomas. J Clin Oncol 2014;5s:A2528.
18. Thomas JP, Tutsch KD, Cleary JF, et al. Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol. Cancer Chemother Pharmacol 2002;50:465-72.
19. Mahadevan D, Plummer R, Squires MS, et al. A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors. Ann Oncol 2011;22:2137-43.
20. Le Tourneau C, Faivre S, Laurence V, et al. Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies. Eur J Cancer 2010;46:3243-50.
21. Massard C, Soria JC, Anthoney DA, et al. A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclindependent kinases (CDK2, 1 and 4) reveals unexpected hepatotoxicity in patients with solid tumors. Cell Cycle 2011;10:963-70.
22. Sausville E, Lorusso P, Carducci M, et al. Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors. Cancer Chemother Pharmacol 2014;73:539-49.
23. Daud AI, Ashworth MT, Strosberg J, et al. Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors. J Clin Oncol 2015;33:1060-6.
24. Karp JE, Thomas BM, Greer JM, et al. Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias. Clin Cancer Res 2012;18:6723-31.
25. Do K, Doroshow JH, Kummar S. Wee1 kinase as a target for cancer therapy. Cell Cycle 2013;12:3159-64.
26. Guertin AD, Li J, Liu Y, Hurd MS, et al. Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy. Mol Cancer Ther 2013;12:1442-52.
27. Bridges KA, Hirai H, Buser CA, et al. MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells. Clin Cancer Res 2011;17:5638-48.
28. Sarcar B, Kahali S, Prabhu AH, et al. Targeting radiation-induced G(2) checkpoint activation with the Wee-1 inhibitor MK-1775 in glioblastoma cell lines. Mol Cancer Ther 2011;10:2405-14.
29. Osman AA, MonroeMM, Ortega Alves MV, et al.Wee-1 kinase inhibition overcomes cisplatin resistance associated with high-risk TP53 mutations in head and neck cancer through mitotic arrest followed by senescence. Mol Cancer Ther 2015;14:608-19.
30. Schöffski P, Besse B, Gauler T, et al. Efficacy and safety of biweekly i.v. administrations of the Aurora kinase inhibitor danusertib hydrochloride in independent cohorts of patients with advanced or metastatic breast, ovarian, colorectal, pancreatic, small-cell and non-small-cell lung cancer: a multitumour, multi-institutional phase II study. Ann Oncol 2015;26:598-607.
31. Venkatakrishnan K, Kim TM, Lin CC, et al. Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: pharmacokinetics and recommended phase 2 dose. Invest New Drugs 2015;33:942-53.
32. Matulonis UA, Sharma S, Ghamande S, et al. Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. Gynecol Oncol 2012;127:63-9.
33. Schöffski P, Awada A, Dumez H, et al. A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours. Eur J Cancer 2012;48:179-86.
34. StadlerWM,Vaughn DJ, Sonpavde G, et al. An open-label, single-arm, phase 2 trial of the Polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer. Cancer 2014;120:976-82.
35. Döhner H, Lübbert M, Fiedler W, et al. Randomized, phase 2 trial of lowdose cytarabine with or without volasertib in AML patients not suitable for induction therapy. Blood 2014;124:1426-33.